Iovance Biotherapeutics (IOVA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.55 (+6.49%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Key Insights

Critical company metrics and information
  • Share Price

    $9.03
  • Market Cap

    $2.75 Billion
  • Total Outstanding Shares

    304.78 Million Shares
  • Total Employees

    557
  • Dividend

    No dividend
  • IPO Date

    October 15, 2010
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.iovance.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$41.95 Million
Net Cash Flow, Continuing$-65.82 Million
Net Cash Flow From Operating Activities$-58.97 Million
Net Cash Flow From Investing Activities, Continuing$-48.80 Million
Exchange Gains/Losses$1.25 Million
Net Cash Flow$-64.57 Million
Net Cash Flow From Financing Activities, Continuing$41.95 Million
Net Cash Flow From Operating Activities, Continuing$-58.97 Million
Net Cash Flow From Investing Activities$-48.80 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Gross Profit$18.73 Million
Revenues$58.55 Million
Income Tax Expense/Benefit, Deferred$-1.52 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations Before Tax$-85.06 Million
Income/Loss From Continuing Operations After Tax$-83.54 Million
Costs And Expenses$147.62 Million
Net Income/Loss$-83.54 Million
Basic Earnings Per Share$0.28
Income Tax Expense/Benefit$-1.52 Million
Net Income/Loss Attributable To Parent$-83.54 Million
Diluted Average Shares$303269.00
Net Income/Loss Available To Common Stockholders, Basic$-83.54 Million
Operating Expenses$107.80 Million
Research and Development$68.25 Million
Operating Income/Loss$-89.07 Million
Benefits Costs and Expenses$143.62 Million
Basic Average Shares$303269.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Cost Of Revenue$39.82 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$0.28
Other Operating Expenses$39.55 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Fixed Assets$112.52 Million
Assets$991.12 Million
Inventory$38.58 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$460.00 Million
Other Non-current Assets$380.02 Million
Noncurrent Assets$492.54 Million
Other Current Liabilities$86.37 Million
Equity Attributable To Parent$773.46 Million
Equity$773.46 Million
Liabilities$217.66 Million
Noncurrent Liabilities$99.60 Million
Current Liabilities$118.06 Million
Accounts Payable$31.69 Million
Liabilities And Equity$991.12 Million
Current Assets$498.58 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.